Tag: Passeo-18 Lux

BIOPACT head-to-head non-inferiority randomised controlled trial completes enrolment

Biotronik is proud to announce the completion of enrolment of the investigator-initiated BIOPACT randomised controlled trial (RCT). This non-inferiority study evaluates the safety and...

BIOLUX AV trial demonstrates safety and efficacy of Passeo-18 Lux DCB...

Recent data from the investigator-initiated, randomised controlled trial (RCT), BIOLUX AV, showed that the treatment of dysfunctional haemodialysis access with Biotronik's Passeo-18 Lux drug-coated...

BIOPACT-RCT set to compare Passeo-18 Lux and IN.PACT Admiral DCBs in...

iD3 Medical has announced that it has received approval in Belgium to initiate a randomised controlled trial, BIOPACT-RCT: a physician-initiated multicentre trial evaluating the...

Passeo-18 Lux DCB remains safe and effective at two years with...

Two-year data on the Passeo-18 Lux drug-coated balloon (DCB; Biotronik) continue to validate its safety and effectiveness in intra-inguinal arteries. Gunnar Tepe from the...

Encouraging results for Biotronik’s Passeo-18 Lux drug-coated balloon and Pulsar-18 bare...

Interim data presented at the 2017 Leipzig Interventional Course (LINC; 24-27 January, Leipzig, Germany) has demonstrated encouraging results for Biotronik’s dedicated lower limb intervention...